Photo by nci from unsplash
Lasmiditan is a selective 5-HT1F receptor agonist without vasoconstrictive activity. In this phase 3 double-blind placebo-controlled study, Goadsby et al. show that lasmiditan is efficacious and relatively well tolerated in… Click to show full abstract
Lasmiditan is a selective 5-HT1F receptor agonist without vasoconstrictive activity. In this phase 3 double-blind placebo-controlled study, Goadsby et al. show that lasmiditan is efficacious and relatively well tolerated in the acute treatment of migraine in adults, including those with cardiovascular risk factors or a prior history of cardiovascular events.
Keywords:
phase;
treatment migraine;
placebo controlled;
acute treatment;
double blind
Journal Title: Brain
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Brain
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!